At passage 10, both types of MSCs were positive for the expression of α-smooth muscle actin (α-SMA)– 1(d)) and calponin– 1(h)), two early SMC markers.
All MSCs were positive for MSC makers (CD29, CD44, Sca-1, and CD106) but were negative for non-MSC markers (CD31, CD34, and CD45).
The isolated MSCs were positive for CD29, CD44, CD105 and Flk-1 while negative for CD31, CD34, CD45 and HLA-DR, as described earlier (Cao et al., 2005).
Previous data showed that rat MSCs were positive for CD29 and CD105, but were negative for CD31 and CD34 [8], [8].
Because of the low number of experimental animals it remains to be determined if the cells (mean of 14.23% of MSCs were positive for SH2) or the model were not optimal for appropriate assessment.
MSCs were positive for NRG1 and ERBB2, but negative for ERBB3 and ERBB4.
After three passages, flow cytometry analysis demonstrated that most MSCs were positive for CD29 and CD90 and negative for CD31, CD34, and CD45).
By using RT-PCR, we showed that CPN treated MSCs were positive for MSCs markers such as CD29, CD71, and CD90 and negative for hematopoietic stem cell markers such as CD34 and CD45, left panel).
Flow cytometry analysis showed that these expanded MSCs were positive for CD44 (99.44%, Figure 2(g)), CD90 (99.37%, Figure 2(h)), and negative for the leukocyte common antigens CD34 (1.17%, Figure 2(i)), CD45 (7.12%, Figure 2 j)).
As shown in Figure 1a, MSCs were positive for specific surface markers such as CD105, CD90 and CD29, but negative for the hematopoietic cell-surface markers like CD34 and CD45.
